Phathom Pharmaceuticals, Inc. (PHAT) Financials

PHAT Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 237.0 million 254.8 million
2023-06-30 265.0 million 247.4 million
2023-03-31 144.0 million 234.2 million
2022-12-31 164.8 million 239.6 million

PHAT Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -32.9 million 6.1 million
2023-06-30 -22.2 million 7.3 million
2023-03-31 -39.9 million 7.0 million
2022-12-31 -41.1 million 6.7 million

PHAT Net Income

No data available :(

PHAT Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 213.7 million - 1.3 million
2023-06-30 248.8 million - 1.5 million
2023-03-31 129.6 million 96.6 million 1.7 million
2022-12-31 155.4 million - 1.8 million

PHAT Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 56.8 million
2023-06-30 48.5 million
2023-03-31 42.4 million
2022-12-31 41.3 million

PHAT Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 939000 12.3 million 23.4 million -
2023-06-30 6000 12.8 million 18.9 million -
2023-03-31 214000 11.5 million 18.6 million -
2022-12-31 412000 15.9 million 30.7 million -

PHAT Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 121000
2023-06-30 - 123000
2023-03-31 - 146000
2022-12-31 - 168000

PHAT

Price: $10.04

52 week price:
6.07
17.02

Earnings Per Share: -3.93 USD

P/E Ratio: -1.82

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 521200

Market Capitalization: 612.3 million

Links: